VistaGen Therapeutics (VTGN) to Post Earnings on Wednesday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to announce its Q4 2026 results after the market closes on Wednesday, July 1st. Analysts expect the company to post earnings of ($0.3377) per share and revenue of $0.4010 million for the quarter. Individuals can check the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Monday, June 15, 2026 at 4:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Monday, June 15th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.40 million. During the same period last year, the company posted ($1.67) EPS. On average, analysts expect VistaGen Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Trading Down 1.2%

Shares of VistaGen Therapeutics stock opened at $0.63 on Wednesday. The business has a 50-day moving average price of $0.61 and a two-hundred day moving average price of $0.85. VistaGen Therapeutics has a 1-year low of $0.43 and a 1-year high of $5.14. The company has a market cap of $25.94 million, a P/E ratio of -0.35 and a beta of 0.31.

Institutional Investors Weigh In On VistaGen Therapeutics

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in VistaGen Therapeutics in the fourth quarter valued at $25,000. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics during the 1st quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of VistaGen Therapeutics during the 3rd quarter worth about $39,000. Tudor Investment Corp ET AL acquired a new stake in shares of VistaGen Therapeutics in the 4th quarter valued at about $50,000. Finally, Bank of America Corp DE grew its stake in shares of VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after buying an additional 19,331 shares during the period. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on VTGN shares. Wall Street Zen downgraded VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.